Literature DB >> 1317364

Expression of integrins and other adhesion molecules in Epstein-Barr virus-transformed B lymphoblastoid cells and Burkitt's lymphoma cells.

J Rincon1, J Prieto, M Patarroyo.   

Abstract

Lymphocytes adhere to cells or extracellular matrices to perform functions relating to cytotoxicity, extravasation and tissue localization, as well as modulation of lymphocyte growth and maturation. This adherence is mainly mediated by 3 families of cell-surface adhesion molecules: integrins, immunoglobulin-related molecules and selectins. Since variations in the degree of adherence may affect the pathophysiology of lymphoproliferative disorders, the expression of a large number of adhesion molecules was analysed on Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs), and on EBV-positive or EBV-negative Burkitt's lymphoma (BL) lines, by immunofluorescence flow cytometry and immunoprecipitation with monoclonal antibodies. With regard to the beta 1, beta 2 and beta 3 integrin subfamilies, LCLs strongly expressed CD49d/CD29 (VLA-4), CD11a/CD18 (Leu-CAMa, LFA-1) and CD51/CD61 (vitronectin receptor). These cells also abundantly expressed CD54 (ICAM-1) and CD58 (LFA-3) as well as the "homing receptors" L-selectin (LECAM-1) and CD44. BL lines had considerably lower amounts of VLA-4 than LCLs, and ICAM-1 was expressed only by some of the tumor lines. All other adhesion molecules were absent or minimally expressed in the BL cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317364     DOI: 10.1002/ijc.2910510319

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Predominant role of alpha 4-integrins for distinct steps of lymphoma metastasis.

Authors:  U Gosslar; P Jonas; A Luz; A Lifka; D Naor; A Hamann; B Holzmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

2.  B-lymphoblastoid cell lines from cancer patients.

Authors:  W K Lee; S M Kim; Y S Sim; S G Cho; S H Park; C W Kim; J G Park
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-02       Impact factor: 2.416

3.  Aberrant DNA methylation of integrin α4 in human breast cancer.

Authors:  Sung-Im Do; Eunkyung Ko; So Young Kang; Jeong Eon Lee; Seok Jin Nam; Eun Yoon Cho; Duk-Hwan Kim
Journal:  Tumour Biol       Date:  2014-04-24

4.  Pathogenesis of primary central nervous system lymphoma: invasion of malignant lymphoid cells into and within the brain parenchyme.

Authors:  R Aho; T Ekfors; M Haltia; H Kalimo
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 5.  Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy.

Authors:  N J Sebire; S Haselden; M Malone; E G Davies; A D Ramsay
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

Review 6.  Intercellular adhesion molecule-1.

Authors:  A van de Stolpe; P T van der Saag
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

7.  Evidence that measles virus hemagglutinin initiates modulation of leukocyte function-associated antigen 1 expression.

Authors:  A R Nagendra; C W Smith; P R Wyde
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

8.  Aberrant DNA methylation of integrin alpha4: a potential novel role for metastasis of cholangiocarcinoma.

Authors:  Kyung-Ok Uhm; Jung Ok Lee; Yun Mi Lee; Eun Soo Lee; Hyeon Soo Kim; Sun-Hwa Park
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-05       Impact factor: 4.553

9.  Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells.

Authors:  Barbro Ehlin-Henriksson; Frida Mowafi; George Klein; Anna Nilsson
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

Review 10.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.